Carrageenans have demonstrated enhanced antitumor activity upon depolymerization into disaccharides. However, the pharmacological viability of these disaccharides and their mechanisms of antitumor action remains to be fully elucidated. This study aimed to employ computational tools to investigate the pharmacological properties and molecular targets pertinent to cancer of the disaccharides derived from the primary carrageenans. Analyses of pharmacological properties predicted by the pkCSM and SwissADME servers indicated that the disaccharides possess a favorable pharmacokinetic profile, although they encounter permeability challenges primarily due to their high polarity and low lipophilicity. Target prediction using SwissTarget and PPB2 identified five carbonic anhydrases, which are also targets of oncology drugs, as common targets for the disaccharides. Molecular docking performed with AutoDock Vina revealed that the binding energies of the disaccharides with carbonic anhydrases were comparable to or greater than those of existing drugs that target these lyases. Notably, six of the complexes formed exhibited interactions between the disaccharides and the zinc cofactor, which represents a primary mechanism of inhibition for these targets. Furthermore, molecular dynamics simulations conducted using GROMACS demonstrated a stable interaction between the disaccharides and carbonic anhydrases. These findings offer new insights into the pharmacological properties and mechanisms of action of carrageenan-derived disaccharides, highlighting their potential for further exploration in clinical trials and experimental studies.
The genera Bombax and Pseudobombax (Malvaceae) are widely used in traditional medicine. This narrative review provides a hierarchical appraisal of their phytochemical and pharmacological profiles based on 35 studies, identifying 22 biological activities. A pronounced taxonomic bias was observed, with research heavily concentrated on Bombax ceiba, while other species, particularly within Pseudobombax, remain poorly explored. Hierarchical analysis indicates that Bombax reaches Level I evidence in metabolic and organ-protective activities, whereas Pseudobombax is largely limited to preliminary Levels II–III. Although antioxidant activity is the most frequently reported effect, it is predominantly supported by in vitro assays with limited physiological relevance. A morphological bias was also evident, with studies prioritizing stem bark and leaves over seeds and roots. Overall, the evidence reveals a significant translational gap, marked by the scarcity of pharmacokinetic data and mechanistic studies. Future research should prioritize standardized, mechanism-driven approaches and expand taxonomic coverage to advance the therapeutic potential of these genera.